Targeting LRIG2 overcomes resistance to EGFR inhibitor in glioblastoma by modulating GAS6/AXL/SRC signaling.
Dong M, Xiao Q, Hu J, Cheng F, Zhang P, Zong W, Tang Q, Li X, Mao F, He Y, Yu X, Wan F, Lei T, Guo D, Wang B.
Dong M, et al. Among authors: zong w.
Cancer Gene Ther. 2020 Dec;27(12):878-897. doi: 10.1038/s41417-020-0163-1. Epub 2020 Jan 28.
Cancer Gene Ther. 2020.
PMID: 31988476